CL2017001871A1 - Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatía dilatada (mcd) - Google Patents

Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatía dilatada (mcd)

Info

Publication number
CL2017001871A1
CL2017001871A1 CL2017001871A CL2017001871A CL2017001871A1 CL 2017001871 A1 CL2017001871 A1 CL 2017001871A1 CL 2017001871 A CL2017001871 A CL 2017001871A CL 2017001871 A CL2017001871 A CL 2017001871A CL 2017001871 A1 CL2017001871 A1 CL 2017001871A1
Authority
CL
Chile
Prior art keywords
mcd
treatment
methylsulfonyl
piperidine compounds
dilated cardiomyopathy
Prior art date
Application number
CL2017001871A
Other languages
English (en)
Inventor
Johan Oslob
Danielle Aubele
Robert Mcdowell
Yonghong Song
Arvinder Sran
Jae Kim
Min Zhong
Original Assignee
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myokardia Inc filed Critical Myokardia Inc
Publication of CL2017001871A1 publication Critical patent/CL2017001871A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN PROPORCIONA NUEVOS COMPUESTOS DE PIPERIDINA UREA 4-METILSULFONA-SUSTITUIDOS QUE SON ÚTILES PARA EL TRATAMIENTO DE MIOCARDIOPATIA DILATADA (MCD) Y AFECCIONES ASOCIADAS A DISFUNCIÓN SISTÓLICA O RESERVA SISTÓLICA VENTRICULAR IZQUIERDA Y/O DERECHA. SE DESCRIBEN LA SÍNTESIS Y LA CARACTERIZACIÓN DE LOS COMPUESTOS, ASÍ COMO MÉTODOS PARA TRATAR MCD Y OTRAS FORMAS DE ENFERMEDAD CARDIACA.</p>
CL2017001871A 2015-01-22 2017-07-20 Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatía dilatada (mcd) CL2017001871A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562106571P 2015-01-22 2015-01-22

Publications (1)

Publication Number Publication Date
CL2017001871A1 true CL2017001871A1 (es) 2018-04-13

Family

ID=55275230

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001871A CL2017001871A1 (es) 2015-01-22 2017-07-20 Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatía dilatada (mcd)

Country Status (35)

Country Link
US (1) US9925177B2 (es)
EP (2) EP4234017A3 (es)
JP (1) JP6712275B2 (es)
KR (2) KR20230145504A (es)
CN (2) CN107428719B (es)
AU (3) AU2016209200B2 (es)
BR (1) BR112017015627B1 (es)
CA (1) CA2974370C (es)
CL (1) CL2017001871A1 (es)
CO (1) CO2017008398A2 (es)
CR (1) CR20170370A (es)
DK (1) DK3247707T3 (es)
DO (2) DOP2017000166A (es)
EA (1) EA036923B1 (es)
EC (1) ECSP17054181A (es)
ES (1) ES2953480T3 (es)
FI (1) FI3247707T3 (es)
GT (1) GT201700163A (es)
HK (1) HK1246775A1 (es)
HR (1) HRP20230737T1 (es)
HU (1) HUE063410T2 (es)
IL (5) IL295547A (es)
LT (1) LT3247707T (es)
MX (3) MX2017009540A (es)
PE (2) PE20171511A1 (es)
PH (1) PH12017501279A1 (es)
PL (1) PL3247707T3 (es)
PT (1) PT3247707T (es)
RS (1) RS64432B1 (es)
SG (2) SG10201913047UA (es)
SI (1) SI3247707T1 (es)
TN (1) TN2017000320A1 (es)
UA (1) UA119905C2 (es)
WO (1) WO2016118774A1 (es)
ZA (1) ZA201704777B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10758525B2 (en) 2015-01-22 2020-09-01 MyoKardia, Inc. 4-methylsulfonyl-substituted piperidine urea compounds
IL272573B2 (en) 2017-09-13 2023-10-01 Amgen Inc Sarcomere activating bisamide compounds and their uses
BR112020014428A2 (pt) 2018-01-19 2020-12-01 Cytokinetics, Inc. composto, composição farmacêutica, e, métodos para o tratamento de uma doença cardíaca em um indivíduo, para o tratamento de uma doença ou condição que está associada com cavidade ventricular esquerda pequena e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia do miocárdio ou fibrose cardíaca, para o tratamento de uma doença ou condição selecionada dentre distrofias musculares e doenças de armazenamento do glicogênio e para inibição do sarcômero cardíaco
WO2019150392A1 (en) 2018-02-01 2019-08-08 Srf Limited Pyrazole compounds and preparation thereof
EP3814342B1 (en) 2018-06-26 2022-07-27 Cytokinetics, Inc. Cardiac sarcomere inhibitors
GB201813312D0 (en) 2018-08-15 2018-09-26 Modern Biosciences Ltd Compounds and their therapeutic use
UY38358A (es) 2018-08-31 2020-03-31 Cytokinetics Inc Inhibidores de sarcómeros cardíacos
GB201905520D0 (en) 2019-04-18 2019-06-05 Modern Biosciences Ltd Compounds and their therapeutic use
AU2020279710A1 (en) * 2019-05-19 2021-12-23 MyoKardia, Inc. Treatment of systolic dysfunction
BR112022000474A2 (pt) 2019-07-16 2022-05-17 Myokardia Inc Formas polimórficas de (r)-4-(1-((3-(difluorometil)-1-metil-1h-pirazol-4-il)sulfonil)-1-fluoroetil)-n-(isoxazol-3-il)piperidina-1-carboxamida
CN110407744A (zh) * 2019-08-13 2019-11-05 上海毕得医药科技有限公司 一种1-(4-氨基吡啶-2-基)乙酮的合成方法
CA3180943A1 (en) * 2020-06-15 2021-12-23 Jean-Francois TAMBY Treatment of atrial dysfunction
KR102541297B1 (ko) 2020-08-18 2023-06-09 가톨릭대학교 산학협력단 확장성 심근병 모델 및 이의 제조방법
AU2022229390A1 (en) 2021-03-04 2023-09-21 Cytokinetics, Inc. Cardiac sarcomere inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050250789A1 (en) * 2004-04-20 2005-11-10 Burns David M Hydroxamic acid derivatives as metalloprotease inhibitors
ES2522579T3 (es) * 2004-06-17 2014-11-17 Cytokinetics, Inc. Compuestos, composiciones y métodos
WO2009011850A2 (en) * 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
US8324178B2 (en) * 2008-10-31 2012-12-04 The Regents Of The University Of California Method of treatment using alpha-1-adrenergic agonist compounds
WO2010068452A1 (en) * 2008-11-25 2010-06-17 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
WO2011059021A1 (ja) 2009-11-11 2011-05-19 大日本住友製薬株式会社 ８－アザビシクロ［３．２．１］オクタン－８－カルボキサミド誘導体

Also Published As

Publication number Publication date
US20160243100A1 (en) 2016-08-25
AU2020244490A1 (en) 2020-10-29
CA2974370A1 (en) 2016-07-28
BR112017015627A2 (pt) 2018-03-13
CN111393414A (zh) 2020-07-10
CR20170370A (es) 2017-10-20
KR102585550B1 (ko) 2023-10-10
CN107428719A (zh) 2017-12-01
RS64432B1 (sr) 2023-09-29
AU2020244490B2 (en) 2022-12-01
HK1246775A1 (zh) 2018-09-14
IL286369A (en) 2021-10-31
IL253552B (en) 2019-12-31
EP3247707A1 (en) 2017-11-29
DOP2022000172A (es) 2022-09-30
ES2953480T3 (es) 2023-11-13
IL295547A (en) 2022-10-01
IL279247A (en) 2021-01-31
CN107428719B (zh) 2020-03-27
IL253552A0 (en) 2017-09-28
BR112017015627B1 (pt) 2022-11-16
HRP20230737T1 (hr) 2023-10-13
DOP2017000166A (es) 2017-10-15
EP4234017A3 (en) 2023-10-18
KR20170113578A (ko) 2017-10-12
PH12017501279A1 (en) 2018-01-29
MX2017009540A (es) 2017-10-20
SG10201913047UA (en) 2020-02-27
DK3247707T3 (da) 2023-07-03
KR20230145504A (ko) 2023-10-17
PT3247707T (pt) 2023-08-31
ZA201704777B (en) 2023-07-26
NZ734020A (en) 2023-11-24
AU2016209200B2 (en) 2020-07-02
UA119905C2 (uk) 2019-08-27
LT3247707T (lt) 2023-08-25
TN2017000320A1 (en) 2019-01-16
MX2021010778A (es) 2022-08-11
GT201700163A (es) 2018-10-18
FI3247707T3 (fi) 2023-08-22
EA201791656A1 (ru) 2017-11-30
CN111393414B (zh) 2024-05-07
PL3247707T3 (pl) 2023-12-11
AU2023200361A1 (en) 2023-02-23
SI3247707T1 (sl) 2023-10-30
CA2974370C (en) 2023-10-31
PE20171511A1 (es) 2017-10-20
PE20212253A1 (es) 2021-11-24
AU2016209200A1 (en) 2017-08-10
ECSP17054181A (es) 2019-02-28
SG11201705928XA (en) 2017-08-30
WO2016118774A1 (en) 2016-07-28
IL271034A (en) 2020-01-30
JP6712275B2 (ja) 2020-06-17
EA036923B1 (ru) 2021-01-15
MX2022007040A (es) 2022-06-24
US9925177B2 (en) 2018-03-27
CO2017008398A2 (es) 2017-10-31
EP4234017A2 (en) 2023-08-30
EP3247707B1 (en) 2023-05-31
HUE063410T2 (hu) 2024-01-28
JP2018502883A (ja) 2018-02-01

Similar Documents

Publication Publication Date Title
CL2017001871A1 (es) Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatía dilatada (mcd)
CR20160032A (es) Compuestos de pirimidinodiona contra estados cardíacos
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
CO2019008783A2 (es) Compuestos dinucleotidos ciclicos para el tratamiento del cancer
CL2017002097A1 (es) Sulfonilureas y compuestos relacionados y uso de estos
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
BR112016023558A2 (pt) compostos úteis como imunomoduladores
ECSP17064695A (es) Compuestos y composiciones de alfa-cinamida como inhibidores de hdac8
SV2017005405A (es) Compuestos y composiciones como inhibidores de quinasa raf
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
CL2017000053A1 (es) Anticuerpos de unión a protofibrillas aß
CL2017000290A1 (es) Inhibidores de la proteína kinasa c y métodos de su uso.
CO2017001528A2 (es) Compuestos novedosos de pirimidina sustituidos
CO2017001506A2 (es) Compuestos novedosos de pirimidina sustituidos
CL2016002338A1 (es) Uso de un compuesto que es ácido r-2-4-2-etoxi-3-4-trifluorometilfenoxipropil-tio-2-metilfenoxi acético, para el tratamiento de una enfermedad colestásica intrahepática .
BR112018014590A2 (pt) formulações/composições compreendendo um inibidor de btk
CR20160316A (es) Compuestos derivados de hidroxiformamida y usos del mismo
CU24608B1 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos
SV2016005293A (es) Compuestos de azol amido-sustituidos como inhibidores de tnks1 y/o tnks2
CR20150148A (es) Azaindolinas
CL2020000127A1 (es) Moduladores terapéuticos del modo inverso de la atp sintasa.
DOP2017000196A (es) Derivados de tetrahidropiranil benzamida
CL2017002304A1 (es) Métodos para tratar enfermedades
NZ772098A (en) 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)
UA117286C2 (uk) 2-гетарил-2-(n-r-піролідин-2-іліден)ацетонітрили та спосіб їх отримання (варіанти)